Abstract
Stem and progenitor cell-based regenerative therapies have the potential to cure chronic respiratory diseases. Yan et al.(1) reported a clinical trial of autologous P63(+) progenitor cell transplantation in bronchiectasis patients, highlighting autologous transplantation of P63(+) progenitor cells as a novel candidate therapeutic option to improve pulmonary gas exchange function and quality of life.